Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

Br J Haematol. 2021 Jan;192(2):e38-e42. doi: 10.1111/bjh.17197. Epub 2020 Nov 5.
No abstract available

Keywords: BTK inhibitor; Mantle cell lymphoma (MCL); brexucabtagene autoleucel; chimeric antigen receptor therapy; ibrutinib; non-Hodgkin lymphoma; venetoclax.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Disease Management
  • Female
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Middle Aged
  • Receptors, Chimeric Antigen / therapeutic use*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Receptors, Chimeric Antigen